The second COVID-19 wave in India saw several patients suffering from post-COVID complications, with Mucormycosis being the most concerning and prevalent. Viatris, through its partnership with Gilead, helped exponentially increase the supply of liposomal Amphotericin-B (AmBisome) used in the treatment of Mucormycosis during the second wave in India by close to 50 times the regular supplies.

We partnered with the Institute of Liver and Biliary Sciences (ILBS) in India for the “Healthy Liver, Healthy Delhi” initiative to create awareness and facilitate early screening and detection of hepatitis B and C and screening for liver health. More than 30,000 people have been screened for free under the program.

Mylan’s collaboration with Sagent, a US based pharmaceuticals company, began in 2013 (following the merger with Agila). Later in 2017, Mylan undertook a separate partnership to take the collaboration to the next level. The relationship has become crucial for multiple sites of Viatris Injectables vertical enabling flexibility in our product portfolio across diverse therapeutic categories and in packaging, including Lyophilized, Liquid and Suspension Vials.

Sagent has also been a strong development partner for key technologies. We currently receive business support from them for our manufacturing sites of Specialty Formulation Facility (SFF), and 3P Steriscience (formerly Sterile Product Division). Some of the important molecules that Viatris was able to access through the partnership are Clindamycin, Rocuronium, Acetylcysteine, Cisatracurium & Methyl Prednisolone Acetate.

X-Gen, a US based pharmaceuticals company, has been working with Mylan since 2012 for the Hosur Sterile facility (HSF). This partnership is solely focussed on Levetiracetam Liquid, a grandfather molecule, which has helped HSF to extend its business through other US filings that followed.

Making available affordable HIV self-test kits - The agreement resulted in a 50% decrease in the price of blood-based HIV self-testing, significantly expanding the market and providing more options for the remaining countries. The new test will cost less than $2 in 135 countries.

Pediatric dispersible formulation of Dolutegravir (DTG) - Targeted at saving children lives from HIV, the 10mg strawberry flavoured DTG tablet has resulted in the prevention of premature deaths in low- and middle-income countries. The agreement also lowers the cost significantly from $480 per child to less than $120.

COVID-19 Diagnostics - The global alliance between UNITAID and FIND have resulted in dramatic expansion in local manufacturing of Covid-19 tests and technology transfer in Africa and Latin America. The objective is to produce 144 million tests every year at a ceiling price of US$2.50 globally. Separate partnership between Viatris (South Africa) and Guangzhou Wondfo Biotech (China) supported to enable commercialization and distribution of high-quality Ag RDTs in low- and middle-income countries.

The collaboration dates back to 2009 with CHAI to increase patient uptake, including TDF volumes for first line in Zambia as part of UNITAID's programme to reduce second-line ARV prices. The collaboration aims to accelerate development and introduce DTG to HIV-positive children. We have collaborated with CHAI on several ARV-related initiatives.

Viatris is partnering with the Bill and Melinda Gates Foundation to increase HIV treatment access in low- and lower-middle-income countries. The collaboration grants access to TLD – DTG Volume Guarantee in addition to the ARV & Oral Contraceptive FDC Product Development along with the Children’s Investment Fund Foundation (CIFF).

The partnership is in the areas of ARV & Oral Contraceptive FDC Product Development along with CIFF.

Atomo Diagnostics is Viatris' manufacturing partner in developing markets for the vitro HIV rapid diagnostic self-test. The Viatris HIV Self-Test requires one-fifth the amount of blood required for other tests and produces results in just 15 minutes.

Viatris has partnered with the TB Alliance to increase access to the molecule Pretomanid as part of a three-drug tuberculosis regimen worldwide.

Viatris has signed multiple License Agreements with MPP for drugs in the ARV and Hepatitis space over the years.